Press Release

Kaken to launch “GHRP Kaken 100 Injection” for Diagnosis of Growth Hormone DeficiencyFebruary 23, 2005

 Kaken Pharmaceutical Co., Ltd. (Headquarters: Bunkyo-ku, Tokyo; President: Shiro Inui) announced today its plan to launch “GHRP Kaken 100 Injection” for diagnosis of GH (Growth Hormone) Deficiency on February 25, 2005.

 

 Pralmorelin Hydrochloride is an active ingredient of “GHRP Kaken 100 Injection” and was discovered as a GH releasing hexapeptide by Dr. C. Y. Bowers at Tulane University (New Orleans, LA, USA). Kaken has collaborated with Tulane and commenced its clinical studies in Japan in 1995. It was recently approved by demonstrating high efficacy on diagnosing the ability of GH secretion with securing safety.

 

 This product is a world first agent to check the GH secreting ability by stimulating GH Secretagogue Receptors (GHS-R) and has high precision/reproduction characteristics. Also it requires shorter time in completion than the other existing diagnostics.

Back to list